Resources>Antibody Industry Trends>Biointron Insights: Antibody Industry Report (YTD December 2024 Insights, Trends & Analysis)

Biointron Insights: Antibody Industry Report (YTD December 2024 Insights, Trends & Analysis)

Biointron 2025-01-01

Biointron Insights

This report aims to explore the events and trends of the biopharmaceutical industry in 2024 (YTD December 2024). This year, 22 novel antibody drugs have been approved by at least one regulatory agency around the world.

These drugs range from monoclonal antibodies to bispecifics and antibody-drug conjugates (ADCs). ADCs in particular are extremely exciting as cancer therapies, being projected to surpass USD 50 billion by 2030. What’s more, antibody drug approvals are going global, with the United States remaining at the forefront of antibody drug development, but China quickly catching up.

2024 saw several large collaborations and acquisitions of up to $10 billion in value, primarily for ADCs and multispecifics. The majority of M&A deals worth over USD $1B have been in the first half of 2024. Investment in antibody drug startups focuses heavily on the use of artificial intelligence (AI) and bispecifics for inflammatory and immunology diseases.


Please fill in the form below to download


Recommended Articles
Biointron Insights: Antibody Industry Trends (Q3 2026 Insights, Trends & Analysis)

Biointron's Q3 2026 Antibody Industry Trends report aims to explore the events a……

Sep 30, 2026
November 2026: Bispecifics x AI: From Design to Clinic

Bispecific antibodies (BsAbs) can bind two different antigens simultaneously, of……

Nov 09, 2026
Week 1, November 2026: VNAR vs. VHH: What's the Difference Between Shark and Camelid Single-Domain Antibodies?

When we think of antibodies, sharks and alpacas probably aren't the first an……

Nov 03, 2026
Week 3, October 2026: The Evolving Role of Biomarkers in Antibody-Based Cancer Therapies

Antibody-based cancer therapies have expanded treatment options across multiple ……

Oct 21, 2026

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.